Cargando…

“Life-changing”: the experience of super-responders to biologics in severe asthma

BACKGROUND: There is limited information on the patient’s perspective of how biologic treatments impact their lives. We conducted a qualitative study to explore the patient’s experience of being considered a super-responder from a quality of life perspective. METHODS: Patients with severe asthma ide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lanario, Joseph W., Cartwright, Lucy, Jones, Rupert C., Sayers, Ross, Hyland, Michael E., Masoli, Matthew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702657/ https://www.ncbi.nlm.nih.gov/pubmed/36437459 http://dx.doi.org/10.1186/s12890-022-02241-2

Ejemplares similares

The construction and validation of the Severe Asthma Questionnaire
por: Hyland, Michael E., et al.
Publicado: (2018)

How patient participation was used to develop a questionnaire that is fit for purpose for assessing quality of life in severe asthma
por: Hyland, Michael E., et al.
Publicado: (2018)

Evidence for similarity in symptoms and mechanism: The extra‐pulmonary symptoms of severe asthma and the polysymptomatic presentation of fibromyalgia
por: Hyland, Michael E., et al.
Publicado: (2019)

Preliminary development of a questionnaire to measure the extra-pulmonary symptoms of severe asthma
por: de Felice, Giulio, et al.
Publicado: (2021)

Comparison of the sensitivity of patient-reported outcomes for detecting the benefit of biologics in severe asthma
por: Hyland, Michael E, et al.
Publicado: (2021)

Validation of subscales of the Severe Asthma Questionnaire (SAQ) using exploratory factor analysis (EFA)
por: Lanario, Joseph W., et al.
Publicado: (2020)

The Severe Asthma Questionnaire: sensitivity to change and minimal clinically important difference
por: Masoli, Matthew, et al.
Publicado: (2021)

Use of Health Related Quality of Life in Clinical Trials for Severe Asthma: A Systematic Review
por: Lanario, Joseph W, et al.
Publicado: (2021)

A Single Center Experience of Super-Responders Among Severe Asthma Patients Receiving Treatment with Mepolizumab
por: Atayık, Emel, et al.
Publicado: (2022)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
por: Bagnasco, Diego, et al.
Publicado: (2023)

Saudi Arabian real-life experience with biologic therapy in severe asthma
por: Eldaboussi, Safwat, et al.
Publicado: (2021)

A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences
por: Kotisalmi, Emma, et al.
Publicado: (2020)

Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders
por: Ashina, Sait, et al.
Publicado: (2023)

Correction to: A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences
por: Kotisalmi, Emma, et al.
Publicado: (2020)

Symptom frequency and development of a generic functional disorder symptom scale suitable for use in studies of patients with irritable bowel syndrome, fibromyalgia syndrome or chronic fatigue syndrome
por: Hyland, Michael E., et al.
Publicado: (2019)

Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Identifying “super responders” in pulmonary arterial hypertension
por: Halliday, Stephen J., et al.
Publicado: (2017)

Methotrexate as an oral corticosteroid-sparing agent in severe asthma: the emergence of a responder asthma endotype
por: Knarborg, Malene, et al.
Publicado: (2014)

Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Biological treatments for severe asthma
por: Jin, Hyun Jung
Publicado: (2020)

Biological therapy for severe asthma
por: Dragonieri, Silvano, et al.
Publicado: (2021)

Evaluating minimal important differences and responder definitions for the asthma symptom diary in patients with moderate to severe asthma
por: Globe, Gary, et al.
Publicado: (2019)

Adverse childhood experience and asthma onset: a systematic review
por: Exley, Daniel, et al.
Publicado: (2015)

Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era
por: Jackson, David J, et al.
Publicado: (2021)

Severe asthma and quality of life
por: Hossny, Elham, et al.
Publicado: (2017)

Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience
por: Licari, Amelia, et al.
Publicado: (2017)

COVID-19, severe asthma, and biologics
por: García-Moguel, Ismael, et al.
Publicado: (2020)

Biologic Therapy and Severe Asthma in Children
por: Russo, Daniele, et al.
Publicado: (2021)

Biologics and airway remodeling in severe asthma
por: Varricchi, Gilda, et al.
Publicado: (2022)

Switching Biological Therapies in Severe Asthma
por: Scioscia, Giulia, et al.
Publicado: (2023)

Patient experiences of biologic treatment for severe asthma: the good, the outstanding and the deeply frustrating
por: Denning, Jessica, et al.
Publicado: (2021)

Asthma
por: Shaw, Dominick, et al.
Publicado: (2014)

Real‐life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP
por: Mümmler, Carlo, et al.
Publicado: (2021)

Characteristics of severe asthma patients on biologics: a real-life European registry study
por: Principe, Stefania, et al.
Publicado: (2023)

COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry
por: Hanon, Shane, et al.
Publicado: (2020)

Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab
por: Carpagnano, Giovanna E, et al.
Publicado: (2019)

Metabolomics to identify omalizumab responders among children with severe asthma: A prospective study
por: Carraro, Silvia, et al.
Publicado: (2022)

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
por: Scioscia, Giulia, et al.
Publicado: (2023)

Validity of two common asthma-specific quality of life questionnaires: Juniper mini asthma quality of life questionnaire and Sydney asthma quality of life questionnaire
por: Apfelbacher, Christian Joachim, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rjomtjuoq8mrao9h69ihspi9s8